These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 33532459)

  • 1. Severe asthma: adding new evidence - Latin American Thoracic Society.
    García G; Bergna M; Vásquez JC; Cano Salas MC; Miguel JL; Celis Preciado C; Acuña Izcaray A; Barros Monge M; García Batista N; Zabert I; Mayorga JL; Casanova Mendoza R; Gutierrez M; Montero Arias MF; Urtecho Perez L; Antúnez M; Williams Derby V; Villatoro Azméquita A; Motiño L; De Oliveira MA; Rey Sanchez D; Arroyo M; Rodriguez M
    ERJ Open Res; 2021 Jan; 7(1):. PubMed ID: 33532459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline.
    Holguin F; Cardet JC; Chung KF; Diver S; Ferreira DS; Fitzpatrick A; Gaga M; Kellermeyer L; Khurana S; Knight S; McDonald VM; Morgan RL; Ortega VE; Rigau D; Subbarao P; Tonia T; Adcock IM; Bleecker ER; Brightling C; Boulet LP; Cabana M; Castro M; Chanez P; Custovic A; Djukanovic R; Frey U; Frankemölle B; Gibson P; Hamerlijnck D; Jarjour N; Konno S; Shen H; Vitary C; Bush A
    Eur Respir J; 2020 Jan; 55(1):. PubMed ID: 31558662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
    Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
    Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.
    Albers FC; Müllerová H; Gunsoy NB; Shin JY; Nelsen LM; Bradford ES; Cockle SM; Suruki RY
    J Asthma; 2018 Feb; 55(2):152-160. PubMed ID: 28622052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
    Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
    Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overlapping Effects of New Monoclonal Antibodies for Severe Asthma.
    Domingo C
    Drugs; 2017 Oct; 77(16):1769-1787. PubMed ID: 28948572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
    Bernstein JA; Virchow JC; Murphy K; Maspero JF; Jacobs J; Adir Y; Humbert M; Castro M; Marsteller DA; McElhattan J; Hickey L; Garin M; Vanlandingham R; Brusselle G
    Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary care of asthma: new options for severe eosinophilic asthma.
    Skolnik NS; Carnahan SP
    Curr Med Res Opin; 2019 Jul; 35(7):1309-1318. PubMed ID: 30880484
    [No Abstract]   [Full Text] [Related]  

  • 10. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Stevenson M; Cooper K; Harnan S; Hamilton J; Clowes M; Carroll C; Harrison T; Saha S
    Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of Patients Eligible for Anti-IL-5 Treatment in a Cohort of Adult-Onset Asthma.
    Ilmarinen P; Tuomisto LE; Niemelä O; Kankaanranta H
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):165-174.e4. PubMed ID: 29894793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. As-needed ICS-LABA in Mild Asthma: What Does the Evidence Say?
    Domingo C; Rello J; Sogo A
    Drugs; 2019 Nov; 79(16):1729-1737. PubMed ID: 31584145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
    Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
    Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Targeted Therapies for Uncontrolled Asthma.
    Corren J
    J Allergy Clin Immunol Pract; 2019; 7(5):1394-1403. PubMed ID: 31076057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts.
    Ghassemian A; Park JJ; Tsoulis MW; Kim H
    Allergy Asthma Clin Immunol; 2021 Jan; 17(1):3. PubMed ID: 33407869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
    Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Latin-American Consensus on Difficult-to-Control Asthma. 2008 Update].
    Drugs Today (Barc); 2008 Jun; 44 Suppl 3():1-43. PubMed ID: 19093041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical and economic analysis of Reslizumab use in the treatment of patients with severe allergic eosinophilic asthma].
    Kolbin AS; Avdeev SN; Zhuravleva MV; Gomon YM; Balykina YE; Matveyev NV; Proskurin MA; Fedosenko SV
    Ter Arkh; 2019 Dec; 91(12):47-56. PubMed ID: 32598589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgE and eosinophils as therapeutic targets in asthma.
    Patel TR; Sur S
    Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):42-49. PubMed ID: 27906698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
    Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
    Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.